Latest news with #Mdxhealth
Yahoo
7 days ago
- Business
- Yahoo
Bio-Techne Announces Exosome Diagnostics Divestiture
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar. "Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market." Kelderman continued, "Following this transaction, Bio-Techne will strengthen its foundation as a developer of innovative, high value, high margin products, tools and reagents for the life science research and clinical diagnostics markets. This repositioning of the portfolio enables Bio-Techne to direct additional investments to further strengthen this foundation, while creating an immediate uplift to our sector leading operating margin profile." "ExoDx Prostate is a strong strategic fit with our rapidly growing urology and prostate cancer diagnostic business," said Michael McGarrity, Chief Executive Officer of Mdxhealth. "The ExoDx Prostate test equips men with information to make better decisions and avoid unnecessary and potentially dangerous prostate biopsies. Bio-Techne has done a tremendous job delivering this necessary information to patients and growing the base of physicians leveraging this tool. We are looking forward to building on this success." Under the terms of the agreement, Bio-Techne will receive $5 million in MDXH stock combined with future considerations. The transaction is expected to be completed during the first quarter of Bio-Techne's fiscal 2026. Bio-Techne will discuss this transaction, as well as its fourth quarter fiscal 2025 performance on its earnings call tomorrow, August 6th, 2025, at 8:00 a.m. CDT. To listen, please dial 1-800-274-8461 or 1-203-518-9814 (for international callers), and reference conference ID: TECHQ4. The earnings call can also be accessed via webcast through the following link Forward Looking Statements: Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding our belief about the impact of our pending divestiture of Exosome Diagnostics Inc. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About mdxhealth®Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California, with additional laboratory operations in Plano, Texas. For more information, visit and follow us on social media at: and For more information:info@ LifeSci Advisors (IR & PR)John FrauncesManaging DirectorTel: +1 917 355 2395Jfraunces@ ir@ View original content to download multimedia: SOURCE Bio-Techne Corporation
Yahoo
30-04-2025
- Business
- Yahoo
Mdxhealth to Release First Quarter 2025 Financial Results on May 14
IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title: Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and Webcast Speakers: Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial Officer Date: May 14, 2025 Time: 4:30pm ET/ 22:30 CET Conference Call Dial-in Details: United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800 94 94 506United Kingdom: 0808 238 9064 Conference ID: 10199102 Webcast: The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company's website. About Mdxhealth Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit and follow us on social media at: and MDxHealth info@ LifeSci Advisors (IR & PR)US: +1 949 271 9223ir@ Sign in to access your portfolio
